Prenetics Global Ltd (symbol PRE) reported that Chief Financial Officer Hoi Chun Lo exercised previously granted Restricted Stock Units (RSUs) into Class A Ordinary Shares on August 21, 2026. He acquired 32,736 Class A Ordinary Shares at $0.0001 per share and 45,815 Class A Ordinary Shares at $0.00 per share through RSU settlements.
The underlying RSU awards were granted under Prenetics Global Ltd's 2022 Share Incentive Plan. Footnotes state that each RSU represents a contingent right to receive one Class A Ordinary Share, that some grants were adjusted following a 1-for-15 reverse stock split, and that vested RSUs are settled in shares at Lo's election in line with the company’s insider trading policy.
Prenetics Global Ltd (PRE) director and CEO Danny Sheng Wu Yeung reported multiple equity transactions. On August 20, 2026 he exercised 53,953 Class A Ordinary Shares from 809,295 Restricted Stock Units at an exercise price of $0.0001 per share equivalent, then transferred 49,912 shares to an ex-spouse pursuant to a domestic relations order. He also purchased a total of 24,681 Class A Ordinary Shares in open-market transactions on August 20 and 24, 2026 at prices between $18.31 and $21.40 per share. The RSUs were granted under the 2022 Share Incentive Plan and were adjusted following a 1-for-15 reverse stock split.
Prenetics Global Limited (NASDAQ: PRE), parent of premium health brand IM8, announced a multi-year global partnership with actress and producer Lily Collins, who becomes IM8’s first film-and-television Global Ambassador and a shareholder in Prenetics. She joins an equity-aligned roster that includes David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty and Inter Miami CF, and will feature across IM8’s global marketing and product initiatives.
IM8’s flagship Daily Ultimate Essentials has delivered over 57 million servings since its December 2024 launch and currently ships about 200,000 servings per day, with operations in 46 countries and 54% of revenue generated outside the United States. IM8 has reached roughly $251 million in annualized revenue run-rate within 20 months. Driven largely by IM8’s growth, Prenetics raised its full-year 2026 revenue guidance to $220–$230 million and initiated 2027 guidance of $400 million or more. The company achieved positive consolidated Adjusted Free Cash Flow in July 2026 and expects to remain positive for the full third quarter of 2026 and beyond, while expanding its pipeline with IM8 Hydration in Q4 2026 and a premium gummies line in the first half of 2027.
Prenetics Global Limited reported strong growth in its consumer health business for the quarter ended June 30, 2026. Total revenue from continuing operations reached $46.5 million, up 29.3% sequentially and about 3.9x year over year. IM8 contributed $45.0 million, growing 33.2% quarter over quarter and about 4.6x year over year, with IM8 gross margin improving to 65% from 57% a year earlier.
Despite this growth, the company recorded a Q2 net loss of $8.98 million and an Adjusted EBITDA loss of $19.03 million, as acquisition marketing spend rose to $35.7 million. For the first half of 2026, revenue was $82.4 million versus $20.2 million in 2025, while the Adjusted EBITDA loss widened to $24.6 million. July 2026 was the strongest month to date, with revenue of $20.9 million, an IM8 annualized revenue run-rate of roughly $251 million, and the company’s first month of positive consolidated Adjusted Free Cash Flow, which management expects to remain positive from the third quarter onward.
Prenetics closed a $1 billion non-dilutive growth financing facility with General Catalyst’s Customer Value Fund, designed to fund up to 70% of IM8’s marketing spend based on cohort performance. The company raised full-year 2026 guidance to $220–230 million in total revenue, with IM8 expected to generate $215–222 million, and initiated 2027 IM8 revenue guidance of at least $400 million. The balance sheet showed $59.1 million in cash and $50.3 million in current financial assets with no borrowings, following divestitures of ACT Genomics, Europa and Insighta to focus on IM8 and CircleDNA.
Prenetics Global Limited announced the appointment of Caroline Levy as an independent director to its Board, effective August 17, 2026. She will serve on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, replacing Dr. Darshan Shah on those committees while he remains an independent director on the Board.
The company also highlighted its flagship brand IM8, described as the fastest-growing premium supplement brand, with over $200 million in annualized run-rate revenue achieved within 18 months of launch, shipping to 43 countries and delivering about 200,000 servings daily. Prenetics plans to report second quarter 2026 results on August 18, 2026, via a live webcast.
Prenetics Global Ltd reported an initial insider ownership filing for Tat Thuan Yen on a Form 3. Yen is identified as an officer, serving as VP, Finance of IM8 (US) LLC, an affiliated entity. The filing does not list any equity transactions or report any specific security holdings, and it includes an exhibit described as a Power of Attorney.
Prenetics Global Limited entered into a growth financing arrangement for its IM8 business under a Customer Investment Agreement with GC Customer Value Arranger, LLC. Investors may fund up to an aggregate maximum of $1,000,000,000 for IM8’s sales and marketing growth efforts.
For each month, investors can fund up to 70% of IM8’s growth spend, and IM8 must remit a share of collections from customers first acquired in that month until an investor return cap is reached or 10 years elapse. The investor return cap per cohort is the lesser of an amount yielding a 30% internal rate of return across all cohorts in a year and a return multiple ranging from 1.035x to 1.170x of the Investment Amount. The commitment runs through and including August 11, 2028, and is guaranteed jointly and severally by IM8 Limited and Prenetics Limited.
Prenetics states that the structure is intended to deliver cash flow benefits to support IM8’s customer acquisition, but cautions that the impact of the arrangement is unpredictable and may not function as expected. Failure to achieve its objectives, or constraints on incurring additional indebtedness under related covenants, could materially and adversely affect its business, financial condition and results of operations, and the company may still require additional capital.
Prenetics Global Ltd director Hudson Blake Leogrande reported equity award activity. On August 4, 2026, 2,001 Restricted Stock Units that had vested on June 4, 2026 were settled into 2,001 Class A Ordinary Shares at an exercise price of $0.0000 per share. After these transactions, he directly held 4,001 Class A Ordinary Shares and 20,003 RSUs outstanding under the 2022 Share Incentive Plan.
Prenetics Global Limited, a Cayman Islands holding company with operations primarily in Hong Kong and other jurisdictions outside mainland China, files a second amendment to its 2025 annual report to revise key disclosures following SEC comments. The update clarifies its holding-company structure, cash flows within the group, non-IFRS metrics and Hong Kong/PRC-related risks.
The business generated all revenue outside mainland China and has two dormant PRC subsidiaries with no material assets. Management explains that, based on PRC counsel, current PRC approvals are not required, but future rule changes could affect operations and overseas listing. The company highlights HFCAA exposure but notes it was not a Commission-Identified Issuer for 2025 because its Hong Kong auditor is inspected by the PCAOB. It reports substantial net losses from 2023–2025, heavy marketing spend to grow CircleDNA and IM8, and significant internal cash transfers, while stating it has paid no dividends and does not plan near-term distributions. Prenetics also discloses holding approximately 510 Bitcoin as a long-term treasury asset, emphasizing valuation volatility and evolving regulatory and tax risks alongside broader operational, data, and governance risk factors.
Prenetics Global Limited closed a $1 billion growth financing arrangement with General Catalyst’s Customer Value Fund to scale its IM8 wellness brand. The facility can finance up to 70% of IM8’s marketing spend by monthly customer cohort, with General Catalyst receiving a capped share of cohort income until a fixed multiple is repaid.
No equity, warrants, or convertible instruments are issued, there is no fixed maturity or financial covenants, and recovery is limited to revenue from funded cohorts. The arrangement is classified as a financial liability, with the return component recorded as interest expense, leaving gross margin and operating expense classification unchanged. Prenetics reports approximately $139.7 million in combined cash, investments, and escrow and no debt as of May 31, 2026.
IM8 is described as the fastest-growing premium supplement brand, having delivered over 50 million servings and currently about 200,000 servings daily across 43 markets. IM8 generated preliminary unaudited June 2026 revenue of about $17 million, and FY 2026 IM8 revenue guidance has been raised to $210–220 million from $190–210 million. FY 2025 IM8 revenue was $60 million, and management expects IM8 to reach $300 million in annualized run-rate revenue by year-end 2026 and at least $400 million in 2027 revenue. Across 248,536 customers, every $1 of customer acquisition spend has generated $1.44 in cumulative gross profit on a blended basis.